Maroteaux-Lamy syndrome is an autosomal-recessive disorder due to the deficit of the lysosomal enzyme, arylsulfatase B (ARSB). Among the numerous genomic lesions reported till now, the sequence variant, c.1151G>A (p.S384N), has been associated with a severe phenotype in more than 10% of the patients. We now report the first in vivo demonstration of the polymorphic nature of p.S384N, revealed during the segregation analysis in a family at risk for Maroteaux-Lamy syndrome. The proband, compound heterozygous for c.[944G>A]+[245T>G] (p.[R315Q]+[L82R]), did not carry the p.S384N change, which was instead present in two healthy members of the family, in trans with the causative mutations, p.R315Q and p.L82R, respectively. The hypothesis that p.S384N was a polymorphism was further addressed by reverse dot-blot analysis of 400 control alleles, estimating an allele frequency of 4.5%. To predict the consequences of p.R315Q, p.L82R and p.S384N, we also modeled and compared the three amino-acid changes in the three-dimensional ARSB structure. The in silico analysis predicted a local protein misfolding in the presence of p.R315Q and p.L82R. On the contrary, no evident problem was predicted in the case of p.S384N, occurring on the protein surface, far from the active site. Overall, these findings strongly support the hypothesis that the non-synonymous change p.S384N is a polymorphism. Moreover, our results emphasize the need for caution in drawing conclusions from a novel variant allele before screening at least 50 healthy control subjects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2986599PMC
http://dx.doi.org/10.1038/ejhg.2009.19DOI Listing

Publication Analysis

Top Keywords

maroteaux-lamy syndrome
12
ps384n polymorphism
12
pr315q pl82r
12
segregation analysis
8
analysis family
8
family risk
8
risk maroteaux-lamy
8
ps384n
8
c1151g>a ps384n
8
syndrome conclusively
4

Similar Publications

 This study evaluated and determined, through instrumented three-dimensional (3D) gait analysis, the kinetic, kinematic, and electromyographic profile of patients with mucopolysaccharidosis (MPS) IV and VI.  This crossectional study included 11 patients treated at a rare diseases reference service and evaluated in a movement analysis laboratory. We collected clinical, physical examination, and kinetic, kinematic, and electromyographic data using a 3D movement system, from June 2020 to January 2021.

View Article and Find Full Text PDF

Background: Mucopolysaccharidosis type VI (MPS VI), also known as Manteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase B(ARSB). This syndrome is progressive and affects many tissues and organs, leading to inflammation and scarring. The classic clinical features of Maroteaux-Lamy syndrome are significant impairment of the osteoarticular system with dysostosis multiplex, short stature and motor dysfunction.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the expression of the endocannabinoid receptor 2 (CB2R) in various animal models of lysosomal storage disorders (LSDs) to evaluate its potential as a biomarker and therapeutic target.
  • CB2R levels were significantly increased in the plasma and tissues of specific LSD models, such as Farber disease and mucopolysaccharidosis type IIIA, while other models showed minimal or no increase.
  • Treatment with CB2R agonists not only reduced CB2R and inflammatory markers like MCP-1 in LSD patient cells and mice but also improved their performance in functional tests, suggesting the need for further research on CB2R as a therapeutic target and biomarker for monitoring treatment efficacy.
View Article and Find Full Text PDF

Retinopathy in Mucopolysaccharidoses.

Ophthalmology

November 2024

Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; School of Biological Sciences, Medicine and Health, The University of Manchester, Manchester, United Kingdom. Electronic address:

Purpose: To determine the pattern(s) of onset, variation, and progression of retinopathy in patients with Mucopolysaccharidosis (MPS).

Design: Prospective, longitudinal, observational study.

Participants: Between November 2015 and March 2023, individuals with MPS were recruited from Ophthalmology clinics at the Manchester Royal Eye Hospital, United Kingdom.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!